Last Trading Date: New York, February 6, 2026
- Gilead shares rose 2.10% at the last close on Friday, Feb. 6, 2026, with a slight 0.16% dip after hours, as investors reacted to the FDA’s Yescarta label expansion and positioned ahead of earnings.
- Analyst sentiment remains broadly positive, with multiple firms reiterating Buy/Outperform ratings and price targets clustering in the $145–$156 range ahead of the company’s quarterly results.
- Traders are focused on upcoming earnings and 2026 guidance, particularly updates on oncology growth, HIV franchise stability, and whether the Yescarta label change can drive incremental revenue.
Shares of Gilead Sciences Inc. (NASDAQ: GILD) continued to attract attention on Monday, Feb. 9, 2026, as traders processed a late-week catalyst and positioned ahead of the company’s upcoming quarterly earnings release. Gilead’s stock closed the previous trading session on Friday, Feb. 6, 2026, up 2.10% at $152.50 following news that the U.S. Food and Drug Administration approved a label update for Kite’s Yescarta® cell therapy, expanding its potential patient base in a rare, aggressive form of lymphoma.(Investing)
In after-hours trading, the shares showed a slight pullback, with GILD trading around $152.25, down approximately 0.16% from the Friday close, according to extended trading data.(Investing)
The FDA’s decision to remove limitations of use for Yescarta in relapsed/refractory primary central nervous system lymphoma underscores a broader strategy by Gilead to diversify beyond its core HIV and antiviral franchises into oncology and advanced cell therapies.(Gilead) That regulatory nod appears to have helped the stock reach fresh 52-week highs, though some investors cautioned that the immediate clinical and financial impact may be modest given the rarity of the indication.(simplywall)
Analysts have broadly embraced Gilead’s direction in recent weeks. Several major brokerage firms have raised price targets and reiterated Buy/Outperform ratings heading into earnings. Truist Securities recently lifted its target to $145, highlighting updated prescription trends and product launch expectations, while Citigroup increased its target to $156 with a Buy rating.(Investing) Wolfe Research also issued an Outperform rating with a $155 target, and Bernstein reiterated an Outperform stance with a $135 target, pointing to the potential of Yeztugo and other growth drivers.(marketbeat)
Not all rating moves have been upward: Morgan Stanley trimmed its target slightly to $150 in mid-January while maintaining an Overweight rating, reflecting fine-tuning of long-term assumptions around portfolio breadth.(gurufocus)
The broader market backdrop on Feb. 6 was constructive for equities, particularly in healthcare and biotech segments, with major indices rallying into the close on optimism about economic resilience and easing rate expectations. However, Gilead’s gain outpaced many peers, underlining specific interest in its regulatory progress and near-term catalysts.(Investing)
With Gilead poised to report fourth-quarter and full-year 2025 results after markets close on Feb. 10, 2026, investors are closely watching not just the raw numbers but guidance commentary for 2026. Management’s outlook on HIV franchise performance, Trodelvy and Yeztugo adoption curves, and any updates on pipeline assets will likely be key drivers of trading action in the days following the release.(BusinessWire)